nir178
NSCLC, Non Small Cell Lung Cancer
Novartis PharmaceuticalsPhase 2
—
Rating in progress
nir178 in NSCLC, Non Small Cell Lung Cancer is in the Floatz rating universe. The engine has not yet published a v0.2 rating for this asset. This page will update automatically once scoring completes.
Methodology v0.2 · Dormant